To determine which of the FGFRs and FGFs, other than FGFR1 and FGF2, contribute to survival in cancer cells, we developed four FGFR-overexpressing cells using FGFR1low and FGF2low II-18 cells (Supplementary Fig. 10A) and treated them with osimertinib in the presence of seven exogenous FGF proteins including FGF1, FGF2, FGF7, FGF9, FGF11, FGF12, and FGF18 expressed in NSCLC tumors in the J-ALEX study (data not shown). This evidence concerns the gene FGF2 and non-small cell lung carcinoma.